Indian pharma patent cases "misinterpret IP accords" Pharma Times Last week, it was reported that India's Intellectual Property Appellate Board had reserved its decision on Bayer's appeal against the first compulsory licence granted in India. The licence, for the manufacture of Bayer's advanced liver and kidney ... |
